(Q38595151)

English

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

scientific article published on 29 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

ascending cholangitis

0 references

sclerosing cholangitis

1 reference

based on heuristic

inferred from title

primary sclerosing cholangitis

1 reference

based on heuristic

inferred from title

Gideon M. Hirschfield

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Gregory J Gores

10

object named as

Gregory J Gores

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Michael Trauner

9

object named as

Michael Trauner

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

5

object named as

Tom H Karlsen

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Cyriel Y Ponsioen

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Roger W Chapman

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Olivier Chazouillères

3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Ansgar W Lohse

6

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Massimo Pinzani

7

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Erik Schrumpf

8

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

0 references

publication date

29 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1357-1367

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Surrogate Endpoints And FDA’s Accelerated Approval Process

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Colchicine treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Appropriateness of liver biopsy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

21 January 2018

Consensus methods: characteristics and guidelines for use

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral budesonide in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Tacrolimus for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a cholangiographic prognostic model in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28256

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.28256

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38595151&oldid=1859302007"